Navigation Links
SCOLR Pharma, Inc. Announces Final Closing of Private Placement
Date:6/30/2011

BOTHELL, Wash., June 30, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTC: SCLR) today announced that it has closed the second and final tranche of its previously-announced private placement of its 8% Senior Secured Convertible Debentures due 2013 (the "Debentures").  The Company raised a total of $1,190,200 in the offering.  The Company intends to use the net proceeds for working capital and other general corporate purposes.

Stephen J. Turner, President and Chief Executive Officer, said: "The completion of this offering will allow us to continue to focus on the development of our nutritional business and on our efforts to secure licensing or partnership support for our pharmaceutical products.  We are making good progress in placing our nutritional products on retail shelves and this capital will enable us to be even more aggressive in those efforts."

This second tranche consisted of the sale of an additional $189,000 principal amount of Debentures.  The Debentures, together with accrued and unpaid interest, are convertible at the option of the holders into shares of the Company's common stock at a conversion price equal to $0.05 per share of common stock.  Beginning after the date that is six months from the issuance of the Debentures, the Company may cause mandatory conversion of the Debentures following the continuance for 30 consecutive days of certain conditions, including maintenance of a volume weighted average trading price on each day within such 30 day period of $0.25 per share of common stock.  The Debentures bear interest of 8% per annum, compounded quarterly, and are secured by all the Company's assets.  The Company may, at any time and from time to time, upon 10 days prior notice to the holders, pay in cash all or a portion of the accrued and unpaid interest on the Debentures, or may cause conversion of such accrued and unpaid interest in connection with any mandatory conversion of the Debentures.


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
3. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
4. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
6. SCOLR Pharma, Inc. Announces Initial Closing of Private Placement
7. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
8. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
9. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
10. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014 Pfanstiehl has announced the ... manufactured in the USA ... been recognized for playing a key role in ... of evidence that media supplementation with mannose can ... glycosylation," according to Dr. Christopher Wilcox , ...
(Date:10/1/2014)... 2014 The participants committed to not ... spending their own time adjusting, tweaking and testing virtual ... were ready for judging. , “I enjoyed being involved ... leader. “The entries showed a commendable range exploring ... of the print medium and the creativity of the ...
(Date:10/1/2014)... CA (PRWEB) September 30, 2014 ... user-friendly, cost-effective tools to address sales, training and ... has developed innovative mobile applications to turn ... outlining the agency’s latest customized mobile app creations, ... http://www.studiopmg.com/work . , In partnership with Toyota, StudioPMG ...
(Date:10/1/2014)... MA (PRWEB) September 30, 2014 ... SoundConnect announces four new-hosted collaboration bundles ... bundles deliver high quality conferencing experiences for low, ... packages to choose from, businesses have optimized solutions ... bundled solutions include audio only minutes (1K, ...
Breaking Biology Technology:Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Array Architects Challenges Staff to Create with 3D Printer 2Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2
... 2011 VIVUS, Inc. (Nasdaq: VVUS ), ... therapeutic products, today reported its financial results for the first quarter ... the quarter ended March 31, 2011, VIVUS reported a net loss ... net loss of $18.8 million or $0.23 per share for the ...
... 2, 2011 Richard Resnick, GenomeQuest,s chief executive ... May 3, 2011, at the Biomarker World Congress ... Sequencing on Companion Diagnostics" for pharmaceutical and biotechnology ... and data management technologies. The Biomarker ...
... 2, 2011 Dyadic International, Inc. ("Dyadic") (OTC ... the discovery, development, manufacture and sale of enzyme ... industrial enzyme industries, announced today that its research ... has entered into a research agreement with Sanofi ...
Cached Biology Technology:VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5GenomeQuest to Lead Biomarker World Congress Panel on Applying Whole Genome Sequencing to Developing Companion Diagnostics 2Dyadic Netherlands Enters Into R&D Collaboration With Sanofi Pasteur and EnGen Bio 2
(Date:9/30/2014)... seedless watermelon, salmon, and strawberries all have in common? ... sets of chromosomes and are diploid, these organisms are ... of chromosomesseedless watermelon and salmon have 3 and 4 ... While this might seem surprising, in fact most plant ... discovered over a century ago, but only recently, with ...
(Date:9/30/2014)... environmental scientists and engineers, led by Clemson University ... $5.25 million grant from the U.S. Department of ... make a direct positive impact on South Carolina ... of radioactive contaminants. , "Understanding the scientific and ... environmental aspects of nuclear technologies is imperative if ...
(Date:9/30/2014)... release is available in German . ... among the most expensive foods in the world. Because they ... them. But the distinctive smell of truffles is not only ... scientists under the direction of the Goethe University Frankfurt have ... by soil bacteria which are trapped inside truffle fruiting bodies. ...
Breaking Biology News(10 mins):Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Researchers get $5.25 million to advance nuclear technologies in South Carolina 2On the trail of the truffle flavor 2
... meeting of the United Nations Forum on Forests, now ... the world's forests or, some environmentalists worry, merely an ... U.S. delegation to the U.N. forum is international environmental ... the two-week negotiation will conclude with one or more ...
... Since 1976 the Ebola virus has caused some lethal ... humans do not become directly contaminated from the animal ... from infected carcasses of chimpanzees, gorillas and certain forest ... past several years by IRD scientists and their partners ...
... natural killer T (NKT) cells, the immune system's sentinels, ... invaders or signs of tissue damage and demonstrate a ... , The new studies show that NKT cells crawl ... halt only when they receive a chemical signal to ...
Cached Biology News:U.N. mulls the protection of Earth's forests 2Ebola virus: from wildlife to dogs 2Ebola virus: from wildlife to dogs 3Ebola virus: from wildlife to dogs 4Natural Killers Could Lead to New Hepatitis Treatments 2Natural Killers Could Lead to New Hepatitis Treatments 3Natural Killers Could Lead to New Hepatitis Treatments 4
The PxE Thermal Cycler (PxE) is a licensed 96 well PCR machine, developed to provide all fundamental features for value for money thermal cycling....
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
Biology Products: